Dopamine receptor antagonism by the novel antianxiety drug, buspirone.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000494:pharmacology; D002065:Buspirone; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D007700:Kinetics; D007980:Levodopa / Q000378:metabolism; D008297:Male; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism*
D014151:Anti-Anxiety Agents; D011743:Pyrimidines; D011954:Receptors, Dopamine; D007980:Levodopa; D014446:Tyrosine 3-Monooxygenase; D001058:Apomorphine; D002065:Buspirone; D004298:Dopamine